Natco Pharma- Kothur facility gets 9 observations from USFDA
NEW DELHI: Natco Pharma Thursday said the US health regulator has made nine observations after the completion of inspection of its Kothur formulation facility in Telangana.
The United States Food and Drug Administration (USFDA) conducted the inspection at Kothur facility between May 30-June 5, 2019.
Read Also: Swiss company Actelion moves US court against Natco Pharma over generic of its patented drug
"At the end of the inspection, the facility received 9 observations, with no repeat observations and mostly procedural in nature," Natco Pharma said in a BSE filing.
The company believes that none of the observations are related to data integrity and that they can be addressed within a short period of time, it added.
Natco Pharma said it will provide due justifications and corrective action plan within next 15 working days to address the USFDA observations.
Read Also: Natco Pharma files ANDA for generic version of Bosentan tablets for oral suspension
Shares of Natco Pharma were trading 0.67 per cent lower at Rs 543.30 apiece on BSE.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd